The following information is for U.S. Healthcare Professionals and includes links to Deciphera-sponsored clinical trials that have been presented at congresses or published in peer-reviewed journals. The list of publications below may contain information about doses, uses, formulations, and populations different from product labeling or contain information about investigational compounds or uses not approved by a regulatory authority. The following list of publications is not comprehensive or exhaustive as to any particular topic. Deciphera does not suggest or recommend the use of its products in any manner other than as described in the Prescribing Information. 

May 13, 2025
Vimseltinib
ISPOR

Characterizing Improvements in Physical Functioning with PROMIS-PF and In-trial Exit Interviews: A Mixed-methods Analysis to Understand the Meaningful Changes Experienced by Patients on Vimseltinib in the MOTION Trial
February 05, 2025
Ripretinib
Annals of Surgical Oncology

INSIGHT: A Phase III Trial of Ripretinib Versus Sunitinib in Patients with Advanced GIST with KIT Exon 11 and Exon 17/18 Mutations Who Were Previously Treated with Imatinib
November 19, 2024
Vimseltinib
ISPOR EU

The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review
November 18, 2024
Vimseltinib
ISPOR EU

A Mixed-Methods Analysis to Define Minimum Clinically Importance Differences (MCIDs) in Range of Motion, Physical Function, and Worst Stiffness in Patients with Tenosynovial Giant Cell Tumor (TGCT)
October 23, 2024
DCC-2812
AACR-NCI-EORTC

A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents

For questions regarding any Deciphera publications, please contact medicalinformation@deciphera.com